Breathe Well Live Well
|
Investigational Asthma Treatment Cuts Exacerbation Rates in Half
Pharmacy Times (registration) The study compared the anti-interleukin-5 (IL-5) monoclonal antibody, reslizumab, with placebo in 953 patients with both asthma and elevated blood eosinophil levels. The research team found that patients treated with reslizumab in the first study … |
View full post on asthma – Google News
EurekAlert |
Investigational drug can reduce asthma flareups
Medical Xpress An investigational drug appears to cut the risk of severe asthma attacks in half for patients who have difficulty controlling the disorder with standard medications, according to results from two multicenter clinical trials. Most Popular Stories |
View full post on asthma – Google News
|
Merck Announces Presentation of Phase III Investigational Studies Evaluating …
MarketWatch (press release) DULERA is indicated in the United States for the treatment of asthma in patients 12 years and older.(1) It is not indicated for the relief of acute bronchospasm or for the treatment of COPD. A supplemental new drug application (sNDA) for DULERA for the … |
View full post on asthma – Google News